Drug Use-Results Survey of Betanis Tablets in Japan

Drug Use-Results Survey of Betanis Tablets 25 and 50 mg

This study is to determine the following information.

1. The occurrence of adverse drug reactions in clinical settings.
2. Factors potentially impacting safety, effectiveness, and other aspects.

This survey aims to determine the following information and the need for conducting specified drug use-results surveys and post-marketing clinical studies in patients using Betanis (generic name: mirabegron):

1. The occurrence of adverse drug reactions in clinical settings.
2. Factors potentially impacting safety, effectiveness, and other aspects.

Items of Particular Interest:

• Safety and effectiveness in patients with hepatic impairment and patients with renal impairment.
• Safety and effectiveness when mirabegron is used concomitantly with other drugs (α1 blockers, anticholinergic agents, 5α reductase inhibitors, drugs with a potent CYP3A4-inhibiting effect, drugs with a CYP3A4-inducing effect, drugs metabolized primarily by CYP2D6, and other frequently used drugs).
• The occurrence of cardiovascular adverse events.
• The occurrence of adverse events related to increased intraocular pressure.
• The occurrence of urinary retention

Inclusion Criteria:

• Patients who received mirabegron for the first time for the treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder.